Tutti gli studi
ReclutamentoEsplorativo terapeutico (Fase II)Interventistico

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)

This research study is about a new drug, RTA 408 (also known as Skyclarys), for adults living with Friedreich's ataxia. The main goal is to find out if this medicine is safe to use and if it can help improve symptoms of the condition. Researchers will look at things like how much effort a person can put into exercise and changes in their overall symptoms over time. This is a "Phase 2" study, which means it's an early stage of testing to see if the drug shows promise before potentially moving on to larger studies. The study involves giving participants different doses of the medication and carefully monitoring their health and progress.

A colpo d'occhio

Stato
Reclutamento
Fase
Esplorativo terapeutico (Fase II)
Sponsor
Reata Pharmaceuticals Inc., Reata Pharmaceuticals Inc.
Obiettivo di iscrizione
21
Inizio
15 Nov 2024

Di cosa tratta questo studio?

This study is looking into a new medicine called RTA 408, which you might also hear referred to as Skyclarys. It’s for people who have Friedreich's ataxia, a genetic condition that affects the nervous system and can cause problems with movement and speech. The main idea behind this study is to understand if this new medicine can help manage the symptoms of Friedreich's ataxia and whether it’s safe for people to take.

The study is split into two parts. In the first part, doctors want to see if the medicine helps people with their physical abilities, specifically how much effort they can put into exercise. They'll also be keeping a very close eye on the general safety of the drug and if anyone experiences side effects. The second part focuses on changes in a special score called the mFARS score, which is a way for doctors to measure how Friedreich's ataxia is affecting someone over 48 weeks. Again, safety will be a key focus throughout.

While this is a "Phase 2" study, which means it's still relatively early in the testing process, it's a really important step. It helps researchers gather information about how the drug works in the body and if it has a real potential to make a difference for people with Friedreich's ataxia in the future.

Punti chiave

  • This study is testing a new medicine (RTA 408/Skyclarys) for Friedreich's ataxia.
  • It aims to find out if the medicine is safe and if it can improve symptoms.
  • The study is for adults aged 18 and over, both men and women.
  • Participants will take capsules and have regular health checks and tests.
  • Being in this study could offer new treatment possibilities but also carries risks of side effects.
  • You can stop participating at any time without affecting your normal care.

Chi può essere idoneo?

To be considered for this study, you would need to be 18 years old or older. There is no upper age limit, meaning older adults may also be able to join.

Both men and women are welcome to take part in this research. The study aims to gather information from a wide range of people with Friedreich's ataxia to understand how the medicine might affect different individuals.

Other specific medical checks would be done by the study doctors to make sure it's safe for you to take part and that the study results will be meaningful. These checks would ensure that you meet all the necessary health requirements for the trial.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai 18 anni o più?
  2. Do you have a diagnosis of Friedreich's ataxia?
  3. Sei in grado di partecipare a appuntamenti clinici regolari?
  4. Are you generally in good health apart from your Friedreich's ataxia?
  5. Are you comfortable potentially receiving a placebo (dummy medicine)?
  6. Are you willing to take oral medication (capsules) as instructed?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you join this study, you would take either the RTA 408 (Skyclarys) medicine in a capsule form, or possibly a placebo (a dummy capsule with no active medicine) – this is common in trials to see the true effect of the drug. You would be given either a 2.5 mg or 10 mg capsule of RTA 408, or the 50 mg Skyclarys capsule. The study involves regular visits to the clinic for assessments.

During these visits, doctors and nurses would perform various checks. These could include physical examinations, blood tests, and tests to measure your exercise ability. You would also likely have your symptoms assessed using special scoring systems, like the mFARS score mentioned earlier. The total length of your participation in the study isn't specified here, but trials like this usually involve several months of regular follow-up appointments.

Rischi e benefici potenziali

Taking part in a study like this could offer potential benefits, such as receiving a new treatment for Friedreich's ataxia that isn't yet widely available, and getting regular health check-ups. However, there are also potential risks; the medicine might have side effects, or it might not work for you. You will be closely monitored for any reactions. It’s important to remember that you are free to leave the study at any time, for any reason, without it affecting your usual medical care.

Luoghi (2)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Austria
  • —
    Non verificato
    Italia

Domande comuni

What is Friedreich's ataxia?

Friedreich's ataxia is a genetic condition that affects the nervous system, causing problems with movement, balance, and speech, among other symptoms.

What is RTA 408 (Skyclarys)?

RTA 408, also known as Skyclarys, is the new medicine being tested in this study to see if it can help people with Friedreich's ataxia.

What does 'Phase 2 study' mean?

A Phase 2 study is an early stage of testing a new medicine. It focuses on finding the right dose, checking for side effects, and seeing if the medicine shows promise for treating the condition.

Will I definitely get the active medicine?

In studies like this, some participants often receive a placebo (a dummy medicine) to help researchers understand the true effects of the active drug. You might receive the active medicine or the placebo.

What are 'peak work' and 'mFARS score'?

Peak work is a measure of how much effort you can put into exercise. The mFARS score is a special way doctors assess the different symptoms of Friedreich's ataxia to track changes over time.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamic…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.